Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 295

1.

Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Review.

PMID:
22947595
2.

Everolimus for advanced pancreatic neuroendocrine tumors.

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group..

N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.

3.

Everolimus for the treatment of pancreatic neuroendocrine tumors.

Feldmann G, Bisht S, Schütte U, Haarmann J, Brossart P.

Expert Opin Pharmacother. 2012 Oct;13(14):2073-84. doi: 10.1517/14656566.2012.713348. Review.

PMID:
22873789
4.

Role of everolimus in pancreatic neuroendocrine tumors.

Goldstein R, Meyer T.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1653-65. doi: 10.1586/era.11.145. Review.

PMID:
21932937
5.

Pancreatic neuroendocrine tumors: entering a new era.

Oberstein PE, Remotti H, Saif MW, Libutti SK.

JOP. 2012 Mar 10;13(2):169-73. Review.

6.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Review.

PMID:
20623346
7.

Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.

Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F.

Cancer Res. 2013 Mar 1;73(5):1449-53. doi: 10.1158/0008-5472.CAN-12-3923. Review.

8.

A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.

Yao J, Wang JY, Liu Y, Wang B, Li YX, Zhang R, Wang LS, Liu L.

Med Oncol. 2014 Dec;31(12):251. doi: 10.1007/s12032-014-0251-x. Retraction in: Med Oncol. 2015 Aug;32(8):221.

PMID:
25395378
10.

Everolimus in renal cell carcinoma.

Wang Y.

Drugs Today (Barc). 2010 Aug;46(8):557-66. doi: 10.1358/dot.2010.46.8.1516824. Review.

PMID:
20830316
11.

Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.

Ito T, Okusaka T, Ikeda M, Igarashi H, Morizane C, Nakachi K, Tajima T, Kasuga A, Fujita Y, Furuse J.

Jpn J Clin Oncol. 2012 Oct;42(10):903-11.

12.

Medical treatment of neuroendocrine tumours.

Weber HC.

Curr Opin Endocrinol Diabetes Obes. 2013 Feb;20(1):27-31. doi: 10.1097/MED.0b013e32835c034f. Review.

PMID:
23221494
13.

Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.

Wolin EM.

Chemotherapy. 2014;60(3):143-50. doi: 10.1159/000369780.

PMID:
25766415
14.

Everolimus.

Hasskarl J.

Recent Results Cancer Res. 2014;201:373-92. doi: 10.1007/978-3-642-54490-3_23. Review.

PMID:
24756805
15.

Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.

Peng L, Schwarz RE.

Curr Mol Med. 2013 Mar;13(3):333-9. Review.

PMID:
23331005
16.

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.

Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP.

Cancer. 2009 Jun 1;115(11):2438-46. doi: 10.1002/cncr.24280.

17.

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.

Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, Wolin EM.

Chest. 2013 Apr;143(4):955-62.

PMID:
23187897
18.

Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.

Ramirez-Fort MK, Case EC, Rosen AC, Cerci FB, Wu S, Lacouture ME.

Am J Clin Oncol. 2014 Jun;37(3):266-71. doi: 10.1097/COC.0b013e318277d62f. Review.

PMID:
23241507
19.

Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.

Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R.

Pancreas. 2015 Mar;44(2):181-9. doi: 10.1097/MPA.0000000000000262.

20.

Supplemental Content

Support Center